Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.64 Insider Own31.30% Shs Outstand72.00M Perf Week1.08%
Market Cap40.25M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float53.66M Perf Month3.06%
Income-99.59M PEG- EPS next Q-0.16 Inst Own50.68% Short Float4.02% Perf Quarter-38.29%
Sales13.79M P/S2.92 EPS this Y46.32% Inst Trans-4.12% Short Ratio5.43 Perf Half Y-27.42%
Book/sh0.79 P/B0.65 EPS next Y2.74% ROA-79.78% Short Interest2.16M Perf Year-51.39%
Cash/sh1.45 P/C0.36 EPS next 5Y- ROE-137.79% 52W Range0.35 - 1.20 Perf YTD-22.39%
Dividend Est.- P/FCF- EPS past 5Y- ROI-148.62% 52W High-57.06% Beta2.30
Dividend TTM- Quick Ratio6.25 Sales past 5Y46.14% Gross Margin78.98% 52W Low47.99% ATR (14)0.05
Dividend Ex-Date- Current Ratio6.25 EPS Y/Y TTM- Oper. Margin-625.40% RSI (14)54.34 Volatility8.30% 12.15%
Employees66 Debt/Eq0.18 Sales Y/Y TTM-1.90% Profit Margin-722.06% Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q- Payout- Rel Volume0.55 Prev Close0.53
Sales Surprise- EPS Surprise-15.79% Sales Q/Q-63.79% EarningsMay 07 AMC Avg Volume397.08K Price0.52
SMA2017.45% SMA50-7.81% SMA200-27.80% Trades Volume220,267 Change-2.00%
Date Action Analyst Rating Change Price Target Change
Jan-06-23Upgrade Piper Sandler Neutral → Overweight $2 → $3
Jan-06-23Upgrade Jefferies Hold → Buy $2.50 → $3
Mar-23-22Downgrade Piper Sandler Overweight → Neutral $15 → $4
Jan-07-22Downgrade JP Morgan Overweight → Neutral $30 → $12
Jan-06-22Downgrade Jefferies Buy → Hold
Sep-09-21Initiated SVB Leerink Outperform $29
May-17-21Resumed Piper Sandler Overweight $47
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Nov-10-20Initiated Jefferies Buy $26
Jul-10-24 08:00AM
Jun-05-24 02:30AM
Jun-04-24 09:55AM
May-22-24 04:05PM
May-21-24 08:00AM
09:35AM Loading…
May-16-24 09:35AM
May-07-24 09:56PM
Apr-30-24 04:05PM
Apr-25-24 04:05PM
Apr-09-24 08:00AM
Apr-03-24 08:00AM
Mar-27-24 09:55AM
08:00AM Loading…
Mar-18-24 08:00AM
Mar-12-24 04:05PM
Mar-05-24 04:05PM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Feb-13-24 08:00AM
Jan-05-24 09:40AM
Dec-07-23 04:05PM
Nov-24-23 10:26AM
Nov-20-23 04:05PM
Nov-13-23 08:00AM
Nov-10-23 08:05AM
Nov-07-23 08:00AM
Nov-03-23 04:30PM
06:57PM Loading…
Nov-02-23 06:57PM
Oct-30-23 01:06PM
Oct-26-23 04:05PM
Oct-25-23 08:00AM
Oct-23-23 08:00AM
Oct-03-23 07:30AM
Sep-21-23 07:30AM
Aug-03-23 04:05PM
Jul-27-23 04:05PM
Jul-19-23 07:30AM
Jun-21-23 04:30PM
Jun-07-23 07:30AM
Jun-05-23 06:09AM
May-24-23 05:26PM
May-12-23 05:05PM
May-04-23 07:25PM
Apr-27-23 04:05PM
Apr-17-23 06:51AM
Apr-11-23 06:50PM
Mar-29-23 04:05PM
Mar-09-23 06:25PM
Feb-28-23 04:05PM
Feb-16-23 08:00AM
Feb-14-23 08:00AM
Feb-10-23 07:00AM
Feb-09-23 11:39AM
Feb-08-23 04:05PM
Jan-23-23 07:53AM
Jan-05-23 08:00AM
Dec-14-22 04:05PM
Dec-08-22 08:00AM
Dec-05-22 05:13AM
Nov-04-22 08:05AM
Nov-02-22 04:05PM
Oct-21-22 09:05AM
Oct-19-22 04:15PM
Oct-18-22 07:30AM
Oct-14-22 08:00AM
Sep-29-22 08:40AM
Sep-28-22 04:32PM
Aug-16-22 08:00AM
Aug-04-22 04:05PM
Jul-27-22 04:05PM
Jul-25-22 08:00AM
Jun-27-22 12:20PM
Jun-22-22 08:00AM
Jun-06-22 08:00AM
May-23-22 04:05PM
May-04-22 04:05PM
May-03-22 08:00AM
Apr-27-22 04:05PM
Apr-05-22 09:25AM
Apr-04-22 08:00AM
Mar-22-22 11:09AM
Mar-10-22 04:05PM
Mar-02-22 04:05PM
Feb-11-22 07:00AM
Feb-03-22 04:05PM
Jan-26-22 08:00AM
Jan-18-22 04:21AM
Jan-14-22 04:51PM
Jan-12-22 09:31AM
Jan-11-22 09:12AM
Jan-07-22 12:24PM
Jan-06-22 06:21PM
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nuechterlein CaroleDirectorOct 25 '23Buy0.767,933,6016,004,14911,025,941Oct 27 04:15 PM